Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs

Epilepsia

Volumn 39, Issue SUPPL. 7, 1998, Pages

  Leeder, J Steven ^a,b,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Carbamazepine; Hypersensitivity; Immune reactions; Phenytoin

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENYTOIN;

ANTICONVULSANT THERAPY; AUTOIMMUNITY; DRUG HYPERSENSITIVITY; EPILEPSY; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ANTICONVULSANTS; BIOTRANSFORMATION; CARBAMAZEPINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG HYPERSENSITIVITY; EPILEPSY; GENOTYPE; HUMANS; LIVER; MODELS, IMMUNOLOGICAL; PHENYTOIN; POLYMORPHISM, GENETIC;

EID: 0031787340     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1998.tb01679.x     Document Type: Review

References (46)

1. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992;34:377-95.
2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
3. Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987;36:581-90.
4. Bourdi M, Chen W, Peter RM, et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996;9:1159-66.
5. Lecoeur S, André C, Beaune PH. Tienilic acid-induced autoimmune hepatitis: Anti-liver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 1996;50:326-33.
6. Bourdi M, Tinel M, Beaune PH, et al. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol Pharmacol 1995;45:1287-95.
7. Hargus SJ, Amouzedeh HR, Pumford NR, et al. Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 1994;7:575-82.
8. Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105:179-84.
9. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988;82:1826-32.
10. Pirmohamed M, Graham A, Roberts P, et al. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991;32:741-9.
11. Leeder JS, Riley RJ, Cook VA, et al. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol Exp Ther 1992;263:360-7.
12. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995;155:2285-90.
13. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49:542-6.
14. Hyson C, Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997;24:245-9.
15. Pohl LR, Satoh H, Christ DD, et al. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol 1988; 28:367-87.
16. Houwerzijl J, De Gast GC, Nater JP, et al. Lymphocyte-stimulation tests and patch tests in carbamazepine hypersensitivity. Clin Exp Immunol 1977;29:272-7.
17. Zakrzewska JM, Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10,11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988;82:110-5.
18. Friedmann PS, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994;130:598-604.
19. Spielberg SP, Gordon GB, Blake DA, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305: 722-7.
20. Riley RJ, Maggs JL, Lambert C, et al. An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. Br J Clin Pharmacol 1988;26:577-88.
21. Pirmohamed M, Kitteringham NR, Guenthner TM. et al. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol 1992;43:1675-82.
22. Roy D, Snodgrass WR. Phenytoin metabolic activation: role of cytochrome P-450, glutathione, age and sex in rats and mice. Res Commun Chem Pathol Pharmacol 1988;59:173-90.
23. Roy D, Snodgrass WR. Covalent binding of phenytoin to protein and modulation of phenytoin metabolism by thiols in A/J mouse liver microsomes. J Pharmacol Exp Ther 1990;252:895-900.
24. Riley RJ, Roberts P, Kitteringham NR, et al. Formation of cytotoxic metabolites from phenytoin, imipramine, desipramine, amitriptyline and mianserin by mouse and human hepatic microsomes. Biochem Pharmacol 1990;39:1951-8.
25. Pirmohamed M, Kitteringham NR, Breckenridge AM, et al. The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. Biochem Pharmacol 1992;44:2307-14.
26. Lillibridge JH, Amore BM, Slattery JT, et al. Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab Disp 1996;24:509-14.
27. Munns AJ, De Voss JJ, Hooper WD, et al. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. Chem Res Toxicol 1997;10:1049-58.
28. Spielberg SP, Gordon GB, Blake DA, et al. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther 1981;217:386-9.
29. Uetrecht J, Zahid N. N-chlorination of phenytoin by myeloperoxidase to a reactive metabolite. Chem Res Toxicol 1988;1:148-51.
30. Kubow S, Wells PG. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase. Mol Pharmacol 1989; 35:504-11.
31. Billings RE. Mechanisms of catechol formation from aromatic compounds in isolated rat hepatocytes. Drug Metab Disp 1985;13: 287-90.
32. Furst SM, Sukhai P, McClelland RA, et al. Covalent binding of carbamazepine oxidative metabolites to neutrophils. Drug Metab Disp 1995;23:590-4.
33. Gaedigk A, Spielberg SP, Grant DM. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994;4:142-53.
34. Green VJ, Pirmohamed M, Kitteringham NR, et al. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol 1995;50:1353-9.
35. Gaedigk A, Leeder JS, Grant DM. Tissue-specific expression and alternative splicing in the human microsomal epoxide hydrolase gene. DNA Cell Biol 1997;16:1257-66.
36. Green VJ, Pirmohamed M, Kitteringham NR, et al. Glutathione-S-transferase μ genotype (GSTM1*0) in patients with carbamazepine hypersensitivity. Br J Clin Pharmacol 1995;39:555P.
37. Maguire JH. Quantitative estimation of catechol/methylcatechol pathways in human phenytoin metabolism. Epilepsia 1988;29: 753-9.
38. Lertratanangkoon K, Horning MG. Metabolism of carbamazepine. Drug Metab Disp 1982;10:1-10.
39. Gaedigk A, Pirmohamed M, Park BK, et al. Genetic polymorphisms of NAD(P)H:quinone reductase (NQO1) and catechol O-methyl transferase (COMT) in patients with anticonvulsant hypersensitivity reactions [Abstract]. Proc XIth Int Symp Microsomes Drug Oxidations 1996:P-198.
40. Beaune P, Dansette PM, Mansuy D, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987;84:551-5.
41. Forrester LM, Henderson CJ, Glancy MJ, et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 1992; 281:359-68.
42. Watkins PB, Wrighton SA. Maurel P, et al. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 1985;82:6310-4.
43. Riley RJ, Smith G, Wolf CR, et al. Human anti-endoplasmic reticulum antibodies produced in aromatic anticonvulsant hypersensitivity reactions recognize rodent CYP3A proteins and a similarly regulated human P450 enzyme(s). Biochem Biophys Res Commun 1993;191:32-40.
44. Leeder JS, Gaedigk A, Lu X, et al. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol Pharmacol 1996;49:234-43.
45. Leeder JS, Lu X, Timsit Y, et al. Non-monooxygenase cytochrome P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions. Pharmacogenetics 1998;8:211-25.
46. Roberts BJ. Evidence of proteosome-mediated cytochrome P-450 degradation. J Biol Chem 1997;272:9771-8.